nitrofurantoin mono macro 100 discoloration urine

HematologicĬommon (1% to 10%): Eosinophilia, decreased hemoglobinįrequency not reported: Hemolytic anemia, leukopenia, agranulocytosis, granulocytopenia, megaloblastic anemia, glucose-6-phosphate dehydrogenase deficiency anemia, thrombocytopenia, cyanosis secondary to methemoglobinemia HepaticĬommon (1% to 10%): Elevated AST, elevated ALT These reactions were sometime severe or irreversible but were rarely fatal. After stopping this drug, further deterioration generally halted and total or partial regression occurred in almost 80% of affected patients. A predisposing condition in most of these patients was renal failure, which was often accompanied by anemia, diabetes, electrolyte imbalance, vitamin B deficiency, and debilitating disease. Polyneuropathy, which started peripherally with initial sensory loss and paresthesia but progressed to motor loss (often with severe muscle atrophy), has occurred during therapy. Risk of peripheral neuropathy has been increased with renal dysfunction (CrCl less than 60 mL/min or clinically significant elevated serum creatinine), anemia, vitamin B deficiency, diabetes mellitus, electrolyte imbalance, and debilitating disease. Peripheral neuropathy (which was sometimes severe or irreversible) has occurred fatalities have been reported. Rare (0.01% to 0.1%): Peripheral neuropathy including optic neuritis (sensory and motor involvement), nystagmus, vertigo, dizziness, drowsinessįrequency not reported: Benign intracranial hypertension ( pseudotumor cerebri), bulging fontanels, polyneuropathy (including optic neuritis), sensory loss, paresthesia, motor loss, neuropathy (generally beginning as paresthesia of the lower extremities and the hands and progressing to muscle weakness and wasting), cerebellar dysfunction Uncommon (0.1% to 1%): Abdominal pain, diarrheaįrequency not reported: Dyspepsia, constipation, sialadenitis, pancreatitis, pseudomembranous colitis, Clostridioides difficile-associated diarrhea, parotitis Metabolicįrequency not reported: Acute porphyria, false positive urinary glucose Nervous system Ĭommon (1% to 10%): Nausea, emesis, flatulence The onset of pseudomembranous colitis symptoms has been reported during or after antimicrobial therapy. Many patients who could not tolerate the microcrystalline formulation were able to take the macrocrystals formulation without nausea. These side effects were dose-related and have been minimized by dose reduction. Nausea, emesis, and anorexia occurred most often abdominal pain and diarrhea were less common. For Healthcare ProfessionalsĪpplies to nitrofurantoin: compounding powder, oral capsule, oral suspension. GI effects ( nausea, flatulence, vomiting, anorexia, diarrhea, dyspepsia, constipation, abdominal pain) headache brown discoloration of urine. Last updated on May 22, 2023.Īpplies to nitrofurantoin: oral capsules, oral suspension.

Nitrofurantoin mono macro 100 discoloration urine